Tag: valeant-pharmaceuticals
-
SEC raises concerns about Valeant’s use of ‘Non-GAAP’ measures
The SEC has questioned Valeant's practice of stripping away acquisition-related expenses from its “non-GAAP” or adjusted metrics, given that the drugmaker had been fueling growth through frenzied deal making. In multiple letters, the SEC said Valeant's management is in possession of all the facts and urged for adequate and accurate financial disclosures. “We are concerned…
-
Washington, California sue over pelvic mesh implants
SEATTLE (AP) — Washington state and California sued Johnson & Johnson on Tuesday, saying that for years the company misrepresented the risks of vaginal mesh implants it sold to repair pelvic collapse.
-
Valeant wants Perrigo’s Papa as its new CEO: CNBC, citing Dow Jones
(Reuters) – Valeant Pharmaceuticals International Inc is seeking to name Perrigo Co Plc's Joseph Papa as its new chief executive, CNBC tweeted, citing Dow Jones.
-
Countries on verge of beating malaria face new threat, study says
By Sebastien Malo NEW YORK (Thomson Reuters Foundation) – Nations on the verge of eliminating malaria risk falling short of their goal, just as it lies within reach, due to funding being shifted elsewhere, researchers said on Thursday. Global aid has moved to areas where malaria remains widespread, while internal domestic funding gets diverted to…
-
Exclusive: Makers took big price increases on widely used U.S. drugs
By Caroline Humer NEW YORK (Reuters) – Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found. Together, the price increases on drugs for arthritis, high cholesterol, asthma and other common…
-
In Wisconsin, Trump looks to put rough week behind him
By Steve Holland MILWAUKEE (Reuters) – Donald Trump is fighting to put a difficult week behind him and finish strong on Tuesday in Wisconsin, a state whose primary contest may prove to be a turning point in the race for the Republican presidential nomination. The Republican front-runner is at risk of losing the Midwestern state…
-
Testosterone may lower heart attack risk in older men: study
Older men with clogged arteries who took testosterone therapy seemed to have a lower risk of heart attacks than men who did not take the hormone, a study suggested Sunday. Testosterone is currently considered risky to the heart, and the US Food and Drug Administration mandated last year that manufacturers of all approved testosterone products add…
-
Valeant seeks waiver from lenders related to filing annual report
The company said earlier in the month that a delay in filing its annual report would put it at risk of a default on its $30 billion in debt. Valeant on Wednesday said it was seeking to extend the deadline for filing its annual report to May 31. “The company is comfortable with its current…
-
Valeant cuts 2016 forecasts, says report delay poses default risk
The Canadian drugmaker, the target of U.S. investigations into its business and accounting practices, reiterated that it would delay filing its annual report with U.S. regulators but for the first time raised the specter of a default as a result. As of Sept. 30, Valeant had about $30 billion of long-term debt. The company said…
-
Valeant sets earnings date, shares jump on hope for positive news
(Reuters) – Valeant Pharmaceuticals International Inc , the subject of intense scrutiny over its business practices and pricing policies, said it would release preliminary quarterly results and guidance on March 15, raising hopes the company will serve up some positive news after months of uncertainty. Valeant's stock – which had plunged 24 percent since the…